The DOI matches its Crossref record.
Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy
Open accessAbstract
AIM: To report on clinical outcome and complications of intravitreal injection of crystalline cortisone in patients undergoing pars plana vitrectomy for treatment of proliferative vitreoretinopathy. METHODS: The study included all 16 patients who underwent pars plana vitrectomy for treatment of proliferative vitreoretinopathy, who received an intravitreal injection of 10-20 mg crystalline triamcinolone acetonide at the end of surgery, and who were operated on by the same surgeon. Most of the vehicle of the solution containing the cortisone crystals was removed before performing the injection. Mean follow up time was 1.64 (SD 2.15) months (median 1. 23 months; range 0.20-9.20 months). The study group was compared with a control group which consisted of 144 patients undergoing pars plana vitrectomy for proliferative vitreoretinopathy performed by the same surgeon. RESULTS: In the study group compared with the control group, intraocular inflammation, as estimated clinically by slit lamp biomicroscopy, was lower, appearance of the fundus upon ophthalmoscopy in the first postoperative week was clearer, and postoperative pain in the first two postoperative days was reduced. Intraocular pressure measured at the end of the first postoperative week did not vary significantly between the groups. A pseudohypopyon consisting of cortisone crystals in the inferior anterior chamber angle was detected in one patient. Postoperative infectious endophthalmitis was not encountered. CONCLUSIONS: This pilot study suggests that intravitreal injection of crystalline cortisone with most of the vehicle removed is not toxic to intraocular structures, reduces postoperative intraocular inflammation, and may be a potentially useful additional tool in the treatment of proliferative vitreoretinopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Intravitreal triamcinolone for refractory diabetic macular edema
Martidis, A., Duker, J. S., Greenberg, P. B., Rogers, A. H., Puliafito, C. A., Reichel, E., & Baumal, C. (2002) · Ophthalmology · doi:10.1016/s0161-6420(02)00975-2 · Cited by 1,032
Diabetic Macular Edema: Pathogenesis and Treatment
Bhagat, N., Grigorian, R. A., Tutela, A., & Zarbin, M. A. (2009) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2008.10.001 · Cited by 571
Beer, P. M., Bakri, S. J., Singh, R. J., Liu, W., Peters, G. B., & Miller, M. (2003) · Ophthalmology · doi:10.1016/s0161-6420(02)01969-3 · Cited by 570
Intravitreal Injection of Triamcinolone for Diffuse Diabetic Macular Edema
Jonas, J. B. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.1.57 · Cited by 563
Self-citationIntravitreal triamcinolone acetonide for exudative age related macular degeneration
Jonas, J. B. (2003) · British Journal of Ophthalmology · doi:10.1136/bjo.87.4.462 · Cited by 492
Self-citation
Metadata
- Authors
- Jonas, J. B.
- Venue
- British Journal of Ophthalmology
- Publisher
- BMJ
- Published
- 2000-09-01
- Volume
- 84
- Issue
- 9
- Pages
- 1064-1067
- ISSN
- 0007-1161 (ISSN-L)
- OpenAlex
- W2146755607
- Cited by
- 193
- References
- 0
- FWCI
- 8.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. https://app.cochat.ai/papers/10.1136/bjo.84.9.1064
- The paper
- Jonas, J. B. (2000). Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. British Journal of Ophthalmology. https://doi.org/10.1136/bjo.84.9.1064
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.